Summary
Pfizer Inc.'s 2023 Form 10-K filing reveals a significant revenue decline, primarily driven by the substantial decrease in sales of its COVID-19 related products, Comirnaty and Paxlovid. Despite this, the company completed the transformative acquisition of Seagen, significantly bolstering its oncology portfolio with the addition of four in-line medicines and a promising pipeline. Looking ahead, Pfizer is focusing on strategic priorities including achieving oncology leadership, advancing its pipeline for future growth, maximizing the performance of its newer products, and optimizing its cost structure. The company is navigating a dynamic market influenced by increasing pricing pressures, the ongoing patent expirations of key products, and evolving regulatory landscapes globally, including the impact of the Inflation Reduction Act (IRA) in the U.S. Pfizer's robust R&D efforts and strategic business development activities are key to its long-term value creation strategy.
Financial Highlights
55 data points| Revenue | $59.55B |
| Cost of Revenue | $24.95B |
| Gross Profit | $34.60B |
| SG&A Expenses | $14.77B |
| Interest Expense | $2.21B |
| Net Income | $2.12B |
| EPS (Basic) | $0.38 |
| EPS (Diluted) | $0.37 |
| Shares Outstanding (Basic) | 5.64B |
| Shares Outstanding (Diluted) | 5.71B |
Key Highlights
- 1Total revenues decreased by 42% to $58.5 billion in 2023, largely due to a significant drop in COVID-19 product sales (Comirnaty and Paxlovid).
- 2The acquisition of Seagen was completed in December 2023, adding transformative cancer medicines and strengthening Pfizer's oncology capabilities.
- 3Excluding COVID-19 products, total revenues increased by 7% operationally, driven by growth in products like Nurtec ODT/Vydura, Oxbryta, Abrysvo, Vyndaqel family, and Eliquis.
- 4Pfizer is implementing an enterprise-wide cost realignment program expected to deliver at least $4 billion in net cost savings by 2024, with approximately $1 billion in annual cost synergies expected from the Seagen acquisition by 2026.
- 5The company anticipates a moderate impact from patent expiries in 2024-2025 but expects a more significant impact from 2026 through 2030 as several key products face patent expirations.
- 6Pfizer continues to invest heavily in R&D, with a focus on its core therapeutic areas including inflammation and immunology, internal medicine, oncology, rare diseases, vaccines, and anti-infectives.
- 7The company maintained its commitment to shareholder returns, declaring a quarterly dividend of $0.42 per share, marking its 341st consecutive quarterly dividend.